Contrasting Alpha Tau Medical (NASDAQ:DRTS) & Anika Therapeutics (NASDAQ:ANIK)
Contrasting Alpha Tau Medical (NASDAQ:DRTS) & Anika Therapeutics (NASDAQ:ANIK)
Anika Therapeutics (NASDAQ:ANIK – Get Rating) and Alpha Tau Medical (NASDAQ:DRTS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
安妮卡治疗(纳斯达克：ANIK-GET评级)和阿尔法头医疗(纳斯达克：DRTS-GET评级)都是小盘医疗公司，但哪只股票更具优势？我们将根据这两家公司的分析师建议、机构持股、股息、风险、收益、盈利能力和估值的强弱对它们进行比较。
Insider & Institutional Ownership
内部人与机构所有权
91.6% of Anika Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Alpha Tau Medical shares are held by institutional investors. 3.0% of Anika Therapeutics shares are held by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
安妮卡治疗公司91.6%的股份由机构投资者持有。相比之下，Alpha Tau Medical 1.0%的股份由机构投资者持有。安妮卡治疗公司3.0%的股份由公司内部人士持有。相比之下，Alpha Tau Medical 39.5%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、大型基金管理公司和对冲基金相信，一家公司的长期表现将好于大盘。
Profitability
盈利能力
This table compares Anika Therapeutics and Alpha Tau Medical's net margins, return on equity and return on assets.
此表比较了Anika Treeutics和Alpha Tau Medical的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Anika Therapeutics | -10.33% | -2.49% | -2.05% |
| Alpha Tau Medical | N/A | -49.72% | -33.76% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 安妮卡治疗公司 | -10.33% | -2.49% | -2.05% |
| Alpha Tau医疗公司 | 不适用 | -49.72% | -33.76% |
Analyst Ratings
分析师评级
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| Alpha Tau Medical | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 安妮卡治疗公司 | 0 | 1 | 1 | 0 | 2.50 |
| Alpha Tau医疗公司 | 0 | 0 | 3 | 0 | 3.00 |
Anika Therapeutics currently has a consensus target price of $28.50, suggesting a potential downside of 7.05%. Alpha Tau Medical has a consensus target price of $17.67, suggesting a potential upside of 338.38%. Given Alpha Tau Medical's stronger consensus rating and higher possible upside, analysts clearly believe Alpha Tau Medical is more favorable than Anika Therapeutics.
Anika Treateutics目前的共识目标价为28.50美元，暗示潜在下行7.05%。Alpha Tau Medical的共识目标价为17.67美元，暗示潜在上涨338.38%。鉴于Alpha Tau Medical更强的共识评级和更高的可能上行空间，分析师显然认为Alpha Tau Medical比Anika Treeutics更有利。
Risk & Volatility
风险与波动性
Anika Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Anika Treateutics的贝塔系数为0.97，表明其股价的波动性比标准普尔500指数低3%。相比之下，Alpha Tau Medical的贝塔系数为0.81，这表明其股价的波动性比标准普尔500指数低19%。
Earnings & Valuation
收益与估值
This table compares Anika Therapeutics and Alpha Tau Medical's revenue, earnings per share and valuation.
此表比较了Anika Treeutics和Alpha Tau Medical的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anika Therapeutics | $147.79 million | 3.03 | $4.13 million | ($1.09) | -28.13 |
| Alpha Tau Medical | N/A | N/A | -$27.27 million | N/A | N/A |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 安妮卡治疗公司 | 1.4779亿美元 | 3.03 | 413万美元 | ($1.09) | -28.13 |
| Alpha Tau医疗公司 | 不适用 | 不适用 | -2,727万元 | 不适用 | 不适用 |
Anika Therapeutics has higher revenue and earnings than Alpha Tau Medical.
Anika Treateutics的收入和收益高于Alpha Tau Medical。
Summary
摘要
Anika Therapeutics beats Alpha Tau Medical on 6 of the 11 factors compared between the two stocks.
在两只股票之间的11个因素中，Anika Treeutics在6个因素上击败了Alpha Tau Medical。
About Anika Therapeutics
关于Anika Treateutics
(Get Rating)
(获取评级)
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Anika Treateutics，Inc.是一家联合保护公司，在美国、欧洲和国际上创造和提供骨关节炎(OA)疼痛管理、再生解决方案、软组织修复和骨保护关节技术领域的早期介入整形外科护理的进步。该公司开发、制造和商业化基于透明质酸(HA)技术平台的产品。它的OA疼痛管理产品系列包括Monovisc、Orthovisc、Cingal和Hyvisc，这些产品被证明可以缓解骨关节炎的疼痛；关节保存和修复产品系列包括大约150个骨保存关节技术产品组合、一系列运动医学软组织修复解决方案和整形外科再生解决方案产品。该公司的非整形外科产品系列包括用于非整形外科应用的基于HA的产品，包括粘连屏障产品、高级伤口护理产品、眼科产品以及耳、鼻和喉产品。安妮卡治疗公司成立于1983年，总部设在马萨诸塞州的贝德福德。
About Alpha Tau Medical
关于Alpha Tau Medical
(Get Rating)
(获取评级)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Alpha Tau医疗有限公司是一家临床阶段的肿瘤治疗公司，在以色列和美国从事用于治疗实体癌症的扩散阿尔法放射疗法(Alpha DART)的研究、开发和商业化。其Alpha-DART技术用于皮肤癌、口腔癌、胰腺癌和乳腺癌的临床试验；以及肝细胞癌、多形性胶质母细胞瘤、肺癌等的临床前研究。该公司成立于2015年，总部设在以色列耶路撒冷。
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Anika治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Anika Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。